← 產業報告目錄

Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-06-26頁數 555報告編號 BT2775

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The epigenetics market is expected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation, and translational studies. Technologies such as next-generation sequencing, PCR & qPCR, mass spectrometry, sonication-based chromatin preparation, and methylation arrays enable the analysis of DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs, and chromatin remodeling. These tools support applications across cancer diagnostics, therapeutic target identification, disease classification, treatment response monitoring, developmental biology, immunology, neuroscience, and metabolic disease research. The growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO settings. In addition, demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample preparation solutions, and bioinformatics platforms is improving workflow reproducibility and data reliability. However, market growth continues to be challenged by high sequencing and analysis costs, complex data interpretation, variability in antibody performance, and difficulties in standardizing epigenetic workflows for broader clinical use. “DNA methylation segment is expected to grow at the highest CAGR during the forecast period” The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies. “Next-generation sequencing segment holds the largest share of the market” The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions. “The US is expected to grow at the highest CAGR during the forecast period” The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side – 70% and Demand Side– 30% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5% Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), EpigenTek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), BPS Bioscience, Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), Biomodal (UK), 10x Genomics (US), and Novogene Co., Ltd. (China) are some of the key companies offering epigenetics products and services. Research Coverage This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (declining sequencing costs and time, growing emphasis on population screening programs, technological advancements in epigenetics research, rising demand for epigenetic drugs and epigenetic-based therapeutics), restraints (limited applications of epigenomic data in toxicology, data privacy concerns and security issues), opportunities (emerging applications of epigenetics, integration of multi-omics), and challenges (concerns regarding quality of antibodies, challenges associated with epigenetic editing) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and innovations in the epigenetics market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US), among others, for the epigenetics market
目錄 Table of Contents
1 INTRODUCTION 46 1.1 STUDY OBJECTIVES 46 1.2 MARKET DEFINITION 46 1.3 MARKET SCOPE 46 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 47 1.3.2 INCLUSIONS & EXCLUSIONS 48 1.3.3 YEARS CONSIDERED 49 1.3.4 CURRENCY CONSIDERED 49 1.4 STAKEHOLDERS 50 1.5 SUMMARY OF CHANGES 50 2 EXECUTIVE SUMMARY 51 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 51 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 53 2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET 54 2.4 HIGH-GROWTH SEGMENTS 55 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 56 3 PREMIUM INSIGHTS 57 3.1 EPIGENETICS MARKET OVERVIEW 57 3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY 58 3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59 3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031 59 4 MARKET OVERVIEW 60 4.1 INTRODUCTION 60 4.2 MARKET DYNAMICS 60 4.2.1 DRIVERS 61 4.2.1.1 Declining sequencing costs and time 61 4.2.1.2 Growing emphasis on population-scale screening initiatives 62 4.2.1.3 Technological advancements in epigenetics research 62 4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics 62 4.2.2 RESTRAINTS 63 4.2.2.1 Limited applications of epigenomic data in toxicology 63 4.2.2.2 Data privacy concerns and security issues 63 4.2.3 OPPORTUNITIES 64 4.2.3.1 Emerging applications of epigenetics 64 4.2.3.2 Integration of multi-omics 64 4.2.4 CHALLENGES 64 4.2.4.1 Concerns regarding quality of antibodies 64 4.2.4.2 Challenges associated with epigenetic editing 65 4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65 4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 66 5 INDUSTRY TRENDS 67 5.1 PORTER’S FIVE FORCES ANALYSIS 67 5.1.1 BARGAINING POWER OF SUPPLIERS 68 5.1.2 BARGAINING POWER OF BUYERS 68 5.1.3 THREAT OF NEW ENTRANTS 69 5.1.4 THREAT OF SUBSTITUTES 69 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 69 5.2 MACROECONOMIC OUTLOOK 69 5.2.1 INTRODUCTION 69 5.2.2 GDP TRENDS AND FORECAST 70 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 70 5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY 71 5.3 VALUE CHAIN ANALYSIS 71 5.4 ECOSYSTEM ANALYSIS 73 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 74 5.5 PRICING ANALYSIS 76 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 76 5.5.1.1 Average selling price trend, by instrument, 2023–2025 76 5.5.1.2 Average selling price trend, by kits & reagents, 2023–2025 77 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 77 5.6 TRADE ANALYSIS 78 5.6.1 IMPORT SCENARIO (HS CODE 9027.50) 79 5.6.2 EXPORT SCENARIO (HS CODE 9027.50) 80 5.6.3 IMPORT SCENARIO (HS CODE 3822.00) 81 5.6.4 EXPORT SCENARIO (HS CODE 3822.00) 82 5.7 KEY CONFERENCES & EVENTS, 2026–2027 83 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84 5.9 INVESTMENT & FUNDING SCENARIO 85 5.10 CASE STUDY ANALYSIS 86 5.10.1 CFDNA METHYLOME–FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION 86 5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND VARIANT PROFILING 86 5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS IN AGING RESEARCH 87   5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET 87 5.11.1 INTRODUCTION 87 5.11.2 KEY TARIFF RATES 87 5.11.3 PRICE IMPACT ANALYSIS 88 5.11.4 IMPACT ON COUNTRIES/REGIONS 89 5.11.4.1 US 89 5.11.4.2 Europe 89 5.11.4.3 Asia Pacific 90 5.11.5 IMPACT ON END-USE INDUSTRIES 90 5.11.5.1 Pharmaceutical and biotechnology companies 90 5.11.5.2 Contract research organizations 90 5.11.5.3 Academic and research institutes 91 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 92 6.1 INTRODUCTION 92 6.1.1 KEY TECHNOLOGIES 92 6.1.1.1 DNA methylation conversion technologies 92 6.1.1.2 Chromatin immunoprecipitation/ChIP 92 6.1.1.3 ATAC-based chromatin accessibility profiling 93 6.1.2 COMPLEMENTARY TECHNOLOGIES 93 6.1.2.1 Single-cell partitioning and epigenomic barcoding 93 6.1.2.2 AI/ML-based epigenomic interpretation 93 6.1.3 ADJACENT TECHNOLOGIES 94 6.1.3.1 CRISPR-based epigenome modulation 94 6.1.3.2 Spatial epigenomics 94 6.2 TECHNOLOGY ROADMAP 95 6.3 PATENT ANALYSIS 95 6.3.1 METHODOLOGY 95 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 95 6.3.3 LIST OF KEY PATENTS 97 6.4 FUTURE APPLICATIONS 97 6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET 98 6.5.1 TOP USE CASES AND MARKET POTENTIAL 99 6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS 100 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET 100 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 101 6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES 101   7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 103 7.1 REGIONAL REGULATIONS AND COMPLIANCE 103 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 7.1.2 INDUSTRY STANDARDS 107 7.1.2.1 North America 107 7.1.2.2 Europe 107 7.1.2.3 Asia Pacific 108 7.1.2.4 Rest of the World 108 7.2 SUSTAINABILITY INITIATIVES 108 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 109 7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 109 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113 8.1 DECISION-MAKING PROCESS 113 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 113 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113 8.2.2 KEY BUYING CRITERIA 114 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 115 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 116 9 EPIGENETICS MARKET, BY OFFERING 117 9.1 INTRODUCTION 118 9.2 PRODUCTS 118 9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS PRODUCTS TO PROPEL MARKET 118 9.3 SERVICES 121 9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS TO DRIVE MARKET 121 10 EPIGENETICS MARKET, BY PRODUCT 125 10.1 INTRODUCTION 126 10.2 KITS & REAGENTS 127 10.2.1 ANTIBODIES 131 10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market 131 10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS 134 10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market 134 10.2.3 CHIP-SEQUENCING KITS & REAGENTS 138 10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market 138   10.2.4 BISULFITE CONVERSION KITS & REAGENTS 141 10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth 141 10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 145 10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth 145 10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS 148 10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth 148 10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 152 10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth 152 10.2.8 HISTONES 155 10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth 155 10.2.9 OTHER KITS & REAGENTS 159 10.3 ENZYMES 162 10.3.1 DNA POLYMERASES 165 10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth 165 10.3.2 DNA LIGASES 169 10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth 169 10.3.3 TN5 TRANSPOSASE 172 10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth 172 10.3.4 CONVERSION ENZYMES 176 10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth 176 10.3.5 PROTEIN-MODIFYING ENZYMES 179 10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth 179 10.3.6 OTHER ENZYMES 183 10.4 INSTRUMENTS & ACCESSORIES 186 10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH 186 11 EPIGENETICS MARKET, BY SERVICE 190 11.1 INTRODUCTION 191 11.2 DNA METHYLATION PROFILING SERVICES 191 11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET 191 11.3 CHROMATIN PROFILING SERVICES 195 11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET 195   11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES 198 11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET 198 11.5 SINGLE-CELL EPIGENOMICS SERVICES 202 11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH 202 11.6 MULTI-OMICS SERVICES 205 11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH 205 11.7 OTHER SERVICES 209 12 EPIGENETICS MARKET, BY TECHNOLOGY 213 12.1 INTRODUCTION 214 12.2 NEXT-GENERATION SEQUENCING 214 12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH 214 12.3 PCR & QPCR 218 12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET 218 12.4 MASS SPECTROMETRY 222 12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET 222 12.5 SONICATION 225 12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET 225 12.6 OTHER TECHNOLOGIES 229 13 EPIGENETICS MARKET, BY METHOD 233 13.1 INTRODUCTION 234 13.2 DNA METHYLATION 234 13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH 234 13.3 HISTONE MODIFICATION 238 13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET 238 13.4 OTHER METHODS 242 14 EPIGENETICS MARKET, BY APPLICATION 245 14.1 INTRODUCTION 246 14.2 ONCOLOGY 246 14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET 246 14.3 METABOLIC DISEASES 252 14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH 252   14.4 IMMUNOLOGY 255 14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET 255 14.5 DEVELOPMENTAL BIOLOGY 259 14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET 259 14.6 CARDIOVASCULAR DISEASES 262 14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH 262 14.7 POPULATION SCREENING 266 14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH 266 14.8 OTHER APPLICATIONS 269 15 EPIGENETIC PRODUCTS MARKET, BY END USER 273 15.1 INTRODUCTION 274 15.2 ACADEMIC & RESEARCH INSTITUTES 274 15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH 274 15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 278 15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY TO PROPEL MARKET 278 15.4 HOSPITALS & CLINICS 281 15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET 281 15.5 CONTRACT RESEARCH ORGANIZATIONS 285 15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET 285 16 EPIGENETICS SERVICES MARKET, BY END USER 289 16.1 INTRODUCTION 290 16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 290 16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS 290 16.3 ACADEMIC & RESEARCH INSTITUTES 294 16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH 294 16.4 HOSPITALS & CLINICS 297 16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH 297   17 EPIGENETICS MARKET, BY REGION 301 17.1 INTRODUCTION 302 17.2 NORTH AMERICA 302 17.2.1 US 309 17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market 309 17.2.2 CANADA 314 17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth 314 17.3 EUROPE 319 17.3.1 GERMANY 324 17.3.1.1 Established life sciences supply ecosystem to drive market 324 17.3.2 UK 328 17.3.2.1 Growing emphasis on precision medicine to propel market 328 17.3.3 FRANCE 333 17.3.3.1 Strong oncology research ecosystem to support market growth 333 17.3.4 ITALY 338 17.3.4.1 High incidence of cancer to drive market 338 17.3.5 SPAIN 342 17.3.5.1 Well-established network of research centers and universities to propel market 342 17.3.6 REST OF EUROPE 346 17.4 ASIA PACIFIC 351 17.4.1 CHINA 356 17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth 356 17.4.2 JAPAN 360 17.4.2.1 Increasing collaborations between research & academic organizations to favor growth 360 17.4.3 INDIA 365 17.4.3.1 Expanding genomics infrastructure to drive market 365 17.4.4 AUSTRALIA 369 17.4.4.1 Strong genomics infrastructure to propel market 369 17.4.5 SOUTH KOREA 373 17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth 373 17.4.6 REST OF ASIA PACIFIC 378 17.5 LATIN AMERICA 383 17.5.1 BRAZIL 387 17.5.1.1 Rising prevalence of chronic diseases to drive market 387 17.5.2 MEXICO 392 17.5.2.1 Growing adoption of cutting-edge technologies to drive market 392 17.5.3 REST OF LATIN AMERICA 396 17.6 MIDDLE EAST 401 17.6.1 GCC COUNTRIES 406 17.6.1.1 Saudi Arabia 410 17.6.1.1.1 Growing healthcare expenditure to propel market 410 17.6.1.2 UAE 415 17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth 415 17.6.1.3 Rest of GCC countries 419 17.6.2 REST OF MIDDLE EAST 424 17.7 AFRICA 429 17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH 429 18 COMPETITIVE LANDSCAPE 435 18.1 INTRODUCTION 435 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–MAY 2026 435 18.3 REVENUE ANALYSIS 437 18.4 MARKET SHARE ANALYSIS, 2025 438 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 440 18.5.1 STARS 441 18.5.2 EMERGING LEADERS 441 18.5.3 PERVASIVE PLAYERS 441 18.5.4 PARTICIPANTS 441 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 443 18.5.5.1 Company footprint 443 18.5.5.2 Region footprint 444 18.5.5.3 Product footprint 445 18.5.5.4 Service footprint 446 18.5.5.5 Method footprint 447 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 448 18.6.1 PROGRESSIVE COMPANIES 448 18.6.2 RESPONSIVE COMPANIES 448 18.6.3 DYNAMIC COMPANIES 448 18.6.4 STARTING BLOCKS 448 18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 450 18.6.5.1 Detailed list of key startups/SMEs 450 18.6.5.2 Competitive benchmarking of key startups/SMEs 451 18.7 COMPANY VALUATION AND FINANCIAL METRICS 452 18.7.1 COMPANY VALUATION 452 18.7.2 FINANCIAL METRICS 452 18.8 BRAND COMPARISON 453 18.9 COMPETITIVE SCENARIO 454 18.9.1 PRODUCT/SERVICE LAUNCHES 454 18.9.2 DEALS 455 19 COMPANY PROFILES 456 19.1 KEY PLAYERS 456 19.1.1 THERMO FISHER SCIENTIFIC INC. 456 19.1.1.1 Business overview 456 19.1.1.2 Products/services offered 457 19.1.1.3 Recent developments 460 19.1.1.3.1 Product launches 460 19.1.1.3.2 Deals 460 19.1.1.4 MnM view 461 19.1.1.4.1 Key strengths 461 19.1.1.4.2 Strategic choices 461 19.1.1.4.3 Weaknesses and competitive threats 461 19.1.2 ILLUMINA, INC. 462 19.1.2.1 Business overview 462 19.1.2.2 Products/Services offered 464 19.1.2.3 Recent developments 466 19.1.2.3.1 Product launches 466 19.1.2.3.2 Deals 467 19.1.2.4 MnM view 467 19.1.2.4.1 Key strengths 467 19.1.2.4.2 Strategic choices 467 19.1.2.4.3 Weaknesses and competitive threats 467 19.1.3 MERCK KGAA 468 19.1.3.1 Business overview 468 19.1.3.2 Products/Services offered 469 19.1.3.3 MnM view 471 19.1.3.3.1 Key strengths 471 19.1.3.3.2 Strategic choices 471 19.1.3.3.3 Weaknesses and competitive threats 471 19.1.4 DANAHER CORPORATION 472 19.1.4.1 Business overview 472 19.1.4.2 Products/Services offered 473 19.1.4.3 Recent developments 475 19.1.4.3.1 Deals 475 19.1.4.4 MnM view 475 19.1.4.4.1 Key strengths 475 19.1.4.4.2 Strategic choices 475 19.1.4.4.3 Weaknesses and competitive threats 475   19.1.5 BIO-RAD LABORATORIES, INC. 476 19.1.5.1 Business overview 476 19.1.5.2 Products/Services offered 477 19.1.5.3 MnM view 481 19.1.5.3.1 Key strengths 481 19.1.5.3.2 Strategic choices 481 19.1.5.3.3 Weaknesses and competitive threats 481 19.1.6 REVVITY 482 19.1.6.1 Business overview 482 19.1.6.2 Products/Services offered 483 19.1.7 PACBIO 485 19.1.7.1 Business overview 485 19.1.7.2 Products/Services offered 486 19.1.7.3 Recent developments 487 19.1.7.3.1 Product launches 487 19.1.7.3.2 Deals 488 19.1.8 ACTIVE MOTIF, INC. 489 19.1.8.1 Business overview 489 19.1.8.2 Products/Services offered 489 19.1.8.3 Recent developments 492 19.1.8.3.1 Deals 492 19.1.9 NEW ENGLAND BIOLABS 493 19.1.9.1 Business overview 493 19.1.9.2 Products/Services offered 493 19.1.9.3 Recent developments 495 19.1.9.3.1 Product launches 495 19.1.9.3.2 Deals 496 19.1.10 QIAGEN 497 19.1.10.1 Business overview 497 19.1.10.2 Products/services offered 498 19.1.10.3 Recent developments 499 19.1.10.3.1 Product launches 499 19.1.11 ZYMO RESEARCH CORPORATION 500 19.1.11.1 Business overview 500 19.1.11.2 Products/Services offered 500 19.1.11.3 Recent developments 503 19.1.11.3.1 Product launches 503 19.1.11.3.2 Deals 503 19.1.12 HOLOGIC DIAGENODE 504 19.1.12.1 Business overview 504 19.1.12.2 Products/services offered 505   19.1.13 F. HOFFMANN-LA ROCHE LTD. 508 19.1.13.1 Business overview 508 19.1.13.2 Products/services offered 509 19.1.14 PROMEGA CORPORATION 511 19.1.14.1 Business overview 511 19.1.14.2 Products/services offered 511 19.1.15 EPIGENTEK GROUP INC. 513 19.1.15.1 Business overview 513 19.1.15.2 Products/Services offered 513 19.1.15.3 Recent developments 517 19.1.15.3.1 Product launches 517 19.2 OTHER PLAYERS 519 19.2.1 EPICYPHER 519 19.2.2 FIOS GENOMICS 520 19.2.3 GENOMESCAN 521 19.2.4 CREATIVE BIOGENE 522 19.2.5 BPS BIOSCIENCE, INC. 523 19.2.6 ABNOVA CORPORATION 524 19.2.7 CREATIVE DIAGNOSTICS 525 19.2.8 BIOMODAL 526 19.2.9 10X GENOMICS 527 19.2.10 NOVOGENE CO., LTD. 528 20 RESEARCH METHODOLOGY 529 20.1 RESEARCH DATA 529 20.1.1 SECONDARY DATA 530 20.1.1.1 Key data from secondary sources 530 20.1.2 PRIMARY DATA 531 20.1.2.1 Key data from primary sources 531 20.1.2.2 Key primary participants 531 20.1.2.3 Breakdown of primary interviews 532 20.1.2.4 Key industry insights 533 20.2 MARKET SIZE ESTIMATION 534 20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025 534 20.2.2 SEGMENTAL MARKET SIZE ESTIMATION 537 20.3 MARKET GROWTH RATE PROJECTIONS 538 20.4 DATA TRIANGULATION 540 20.5 FACTOR ANALYSIS 541 20.6 RESEARCH ASSUMPTIONS 541 20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 542   21 APPENDIX 544 21.1 DISCUSSION GUIDE 544 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 550 21.3 CUSTOMIZATION OPTIONS 552 21.4 RELATED REPORTS 552 21.5 AUTHOR DETAILS 553
圖表清單 List of Tables & Figures
TABLE 1 EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS 48 TABLE 2 EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 61 TABLE 3 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 67 TABLE 4 EPIGENETICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM 74 TABLE 5 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, 2023–2025 76 TABLE 6 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, 2023–2025 (USD) 77 TABLE 7 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2023–2025 (USD) 77 TABLE 8 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, BY REGION, 2023–2025 (USD) 78 TABLE 9 IMPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 79 TABLE 10 EXPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 80 TABLE 11 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 81 TABLE 12 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 82 TABLE 13 EPIGENETICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027 83 TABLE 14 RECIPROCAL TARIFF RATES ADJUSTED BY US 87 TABLE 15 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 89 TABLE 16 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 95 TABLE 17 LIST OF KEY PATENTS IN EPIGENETICS MARKET, 2023–2025 97 TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET 100 TABLE 19 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES 102 TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104 TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 114 TABLE 27 KEY BUYING CRITERIA, BY END USER 114 TABLE 28 EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 118 TABLE 29 EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 30 NORTH AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 31 EUROPE: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 32 ASIA PACIFIC: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 33 LATIN AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 34 MIDDLE EAST: EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 35 GCC COUNTRIES: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 36 EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 37 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 38 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 39 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123 TABLE 40 LATIN AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 41 MIDDLE EAST: EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 42 GCC COUNTRIES: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 43 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 126 TABLE 44 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION) 127 TABLE 45 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 46 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 47 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 48 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 49 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 50 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 51 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 52 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 53 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 54 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 55 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 56 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 57 MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 58 GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 59 EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 60 NORTH AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 61 EUROPE: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 62 ASIA PACIFIC: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 63 LATIN AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 64 MIDDLE EAST: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 65 GCC COUNTRIES: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 66 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 67 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 68 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 69 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 70 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 71 MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 72 GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 73 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 74 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 75 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 76 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 77 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 78 MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 79 GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 80 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 82 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 84 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 85 MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 86 GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 87 EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 88 NORTH AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 89 EUROPE: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 90 ASIA PACIFIC: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 91 LATIN AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 92 MIDDLE EAST: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 93 GCC COUNTRIES: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 94 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 95 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 96 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 97 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 98 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 99 MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 100 GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 101 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 102 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 103 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 104 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 105 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 106 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 107 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 108 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 109 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 110 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 111 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 112 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 113 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 114 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 115 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 116 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 117 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 118 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 119 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 120 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 121 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 122 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 123 EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 125 EUROPE: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 127 LATIN AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 128 MIDDLE EAST: EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION) 168 TABLE 129 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 130 EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 131 NORTH AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 132 EUROPE: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 133 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 134 LATIN AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 135 MIDDLE EAST: EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION) 171 TABLE 136 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 137 EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 138 NORTH AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 139 EUROPE: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 140 ASIA PACIFIC: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 141 LATIN AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 142 MIDDLE EAST: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 143 GCC COUNTRIES: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 144 EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 145 NORTH AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 146 EUROPE: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 147 ASIA PACIFIC: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 148 LATIN AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 149 MIDDLE EAST: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 150 GCC COUNTRIES: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 151 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 152 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 153 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 154 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 155 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 156 MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 157 GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 158 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 159 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 160 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 161 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 162 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 163 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 164 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 165 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 186 TABLE 166 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 167 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 168 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 169 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 170 MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 189 TABLE 171 GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 172 EPIGENETICS MARKET, BY SERVICE, 2024–2031 (USD MILLION) 191 TABLE 173 EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 192 TABLE 174 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 175 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 176 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 177 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 178 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 179 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 180 EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 181 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 182 EUROPE: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 183 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 184 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 185 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 186 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 187 EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 199 TABLE 188 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 189 EUROPE: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 190 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 191 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 192 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION) 201 TABLE 193 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 194 EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 202 TABLE 195 NORTH AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 196 EUROPE: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 197 ASIA PACIFIC: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 198 LATIN AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 199 MIDDLE EAST: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 205 TABLE 200 GCC COUNTRIES: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 201 EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 206 TABLE 202 NORTH AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 203 EUROPE: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 205 LATIN AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 206 MIDDLE EAST: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 208 TABLE 207 GCC COUNTRIES: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 208 EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 209 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 210 EUROPE: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 211 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 212 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 213 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION) 211 TABLE 214 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 215 EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 214 TABLE 216 EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 217 NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 218 EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 219 ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 220 LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 221 MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 217 TABLE 222 GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 223 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION) 219 TABLE 224 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 225 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 226 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 227 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 228 MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION) 221 TABLE 229 GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 230 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION) 222 TABLE 231 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 232 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 233 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 234 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 235 MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION) 225 TABLE 236 GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 237 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION) 226 TABLE 238 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 239 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 240 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 241 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 242 MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION) 228 TABLE 243 GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 244 EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 229 TABLE 245 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 246 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 247 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 248 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 249 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 232 TABLE 250 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 251 EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 234 TABLE 252 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION) 235 TABLE 253 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 254 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 255 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 256 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 257 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION) 237 TABLE 258 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 259 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS 238 TABLE 260 EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION) 239 TABLE 261 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 262 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 263 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 264 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 241 TABLE 265 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION) 241 TABLE 266 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION) 241 TABLE 267 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024–2031 (USD MILLION) 242 TABLE 268 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 242 TABLE 269 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 243 TABLE 270 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 243 TABLE 271 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 272 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024–2031 (USD MILLION) 244 TABLE 273 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 274 EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 275 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS 247 TABLE 276 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 249 TABLE 277 NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 249 TABLE 278 EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 279 ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 280 LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 281 MIDDLE EAST: EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 251 TABLE 282 GCC COUNTRIES: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 251 TABLE 283 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 252 TABLE 284 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 285 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 253 TABLE 286 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 287 LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 254 TABLE 288 MIDDLE EAST: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 254 TABLE 289 GCC COUNTRIES: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 255 TABLE 290 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2024–2031 (USD MILLION) 256 TABLE 291 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 256 TABLE 292 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 293 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 257 TABLE 294 LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 258 TABLE 295 MIDDLE EAST: EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2024–2031 (USD MILLION) 258 TABLE 296 GCC COUNTRIES: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 258 TABLE 297 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2024–2031 (USD MILLION) 259 TABLE 298 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 299 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 260 TABLE 300 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 301 LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 302 MIDDLE EAST: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2024–2031 (USD MILLION) 261 TABLE 303 GCC COUNTRIES: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 304 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 263 TABLE 305 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 263 TABLE 306 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 264 TABLE 307 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 264 TABLE 308 LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 309 MIDDLE EAST: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 265 TABLE 310 GCC COUNTRIES: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 311 EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024–2031 (USD MILLION) 266 TABLE 312 NORTH AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 267 TABLE 313 EUROPE: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 267 TABLE 314 ASIA PACIFIC: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 315 LATIN AMERICA: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 316 MIDDLE EAST: EPIGENETICS MARKET FOR POPULATION SCREENING, BY REGION, 2024–2031 (USD MILLION) 269 TABLE 317 GCC COUNTRIES: EPIGENETICS MARKET FOR POPULATION SCREENING, BY COUNTRY, 2024–2031 (USD MILLION) 269 TABLE 318 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 270 TABLE 319 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 270 TABLE 320 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 321 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 271 TABLE 322 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 323 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 272 TABLE 324 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 272 TABLE 325 EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 326 EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 275 TABLE 327 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 275 TABLE 328 EUROPE: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 276 TABLE 329 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 276 TABLE 330 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 331 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 277 TABLE 332 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 333 EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 278 TABLE 334 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 335 EUROPE: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 279 TABLE 336 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 337 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 280 TABLE 338 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 281 TABLE 339 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 340 EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 282 TABLE 341 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 282 TABLE 342 EUROPE: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 283 TABLE 343 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 283 TABLE 344 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 345 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 284 TABLE 346 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 284 TABLE 347 EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 285 TABLE 348 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 349 EUROPE: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 350 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 287 TABLE 351 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 287 TABLE 352 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 287 TABLE 353 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 288 TABLE 354 EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 290 TABLE 355 EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 291 TABLE 356 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 291 TABLE 357 EUROPE: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 292 TABLE 358 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 292 TABLE 359 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 293 TABLE 360 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 293 TABLE 361 GCC COUNTRIES: EPIGENETICS SERVICE MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 293 TABLE 362 EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 294 TABLE 363 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 295 TABLE 364 EUROPE: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 295 TABLE 365 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 366 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 296 TABLE 367 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 296 TABLE 368 GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 297 TABLE 369 EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 298 TABLE 370 NORTH AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 298 TABLE 371 EUROPE: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 372 ASIA PACIFIC: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 373 LATIN AMERICA: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 374 MIDDLE EAST: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION) 300 TABLE 375 GCC COUNTRIES: EPIGENETICS SERVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 376 EPIGENETICS MARKET, BY REGION, 2024–2031 (USD MILLION) 302 TABLE 377 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 303 TABLE 378 NORTH AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 304 TABLE 379 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 380 NORTH AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 381 NORTH AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 382 NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 383 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 306 TABLE 384 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 307 TABLE 385 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 307 TABLE 386 NORTH AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 308 TABLE 387 NORTH AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 308 TABLE 388 US: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 309 TABLE 389 US: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 390 US: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 391 US: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 392 US: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 393 US: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 311 TABLE 394 US: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 312 TABLE 395 US: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 312 TABLE 396 US: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 313 TABLE 397 US: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 313 TABLE 398 CANADA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 314 TABLE 399 CANADA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 400 CANADA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 401 CANADA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 402 CANADA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 403 CANADA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 316 TABLE 404 CANADA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 317 TABLE 405 CANADA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 317 TABLE 406 CANADA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 407 CANADA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 408 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 319 TABLE 409 EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 319 TABLE 410 EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 411 EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 412 EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 413 EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 414 EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 322 TABLE 415 EUROPE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 322 TABLE 416 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 322 TABLE 417 EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 323 TABLE 418 EUROPE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 323 TABLE 419 GERMANY: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 324 TABLE 420 GERMANY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 421 GERMANY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 422 GERMANY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 423 GERMANY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 424 GERMANY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 326 TABLE 425 GERMANY: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 327 TABLE 426 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 327 TABLE 427 GERMANY: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 327 TABLE 428 GERMANY: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 328 TABLE 429 UK: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 328 TABLE 430 UK: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 431 UK: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 432 UK: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 433 UK: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 434 UK: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 331 TABLE 435 UK: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 331 TABLE 436 UK: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 332 TABLE 437 UK: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 332 TABLE 438 UK: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 333 TABLE 439 FRANCE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 333 TABLE 440 FRANCE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 441 FRANCE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 442 FRANCE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 443 FRANCE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 444 FRANCE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 336 TABLE 445 FRANCE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 336 TABLE 446 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 337 TABLE 447 FRANCE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 337 TABLE 448 FRANCE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 338 TABLE 449 ITALY: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 338 TABLE 450 ITALY: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 451 ITALY: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 452 ITALY: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 453 ITALY: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 454 ITALY: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 341 TABLE 455 ITALY: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 341 TABLE 456 ITALY: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 341 TABLE 457 ITALY: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 342 TABLE 458 ITALY: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 342 TABLE 459 SPAIN: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 343 TABLE 460 SPAIN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 461 SPAIN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 462 SPAIN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 463 SPAIN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 464 SPAIN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 345 TABLE 465 SPAIN: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 345 TABLE 466 SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 345 TABLE 467 SPAIN: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 346 TABLE 468 SPAIN: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 346 TABLE 469 REST OF EUROPE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 347 TABLE 470 REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 471 REST OF EUROPE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 472 REST OF EUROPE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 473 REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 474 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 349 TABLE 475 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 350 TABLE 476 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 350 TABLE 477 REST OF EUROPE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 350 TABLE 478 REST OF EUROPE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 351 TABLE 479 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 352 TABLE 480 ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 353 TABLE 481 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 482 ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 483 ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 484 ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 485 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 355 TABLE 486 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 355 TABLE 487 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 355 TABLE 488 ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 356 TABLE 489 ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 356 TABLE 490 CHINA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 357 TABLE 491 CHINA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 492 CHINA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 493 CHINA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 358 TABLE 494 CHINA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 358 TABLE 495 CHINA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 359 TABLE 496 CHINA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 359 TABLE 497 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 359 TABLE 498 CHINA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 360 TABLE 499 CHINA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 360 TABLE 500 JAPAN: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 361 TABLE 501 JAPAN: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 502 JAPAN: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 503 JAPAN: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 504 JAPAN: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 505 JAPAN: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 363 TABLE 506 JAPAN: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 364 TABLE 507 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 364 TABLE 508 JAPAN: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 364 TABLE 509 JAPAN: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 365 TABLE 510 INDIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 365 TABLE 511 INDIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 366 TABLE 512 INDIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 366 TABLE 513 INDIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 514 INDIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 515 INDIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 368 TABLE 516 INDIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 368 TABLE 517 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 368 TABLE 518 INDIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 369 TABLE 519 INDIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 369 TABLE 520 AUSTRALIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 370 TABLE 521 AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 370 TABLE 522 AUSTRALIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 370 TABLE 523 AUSTRALIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 371 TABLE 524 AUSTRALIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 371 TABLE 525 AUSTRALIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 372 TABLE 526 AUSTRALIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 372 TABLE 527 AUSTRALIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 372 TABLE 528 AUSTRALIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 373 TABLE 529 AUSTRALIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 373 TABLE 530 SOUTH KOREA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 374 TABLE 531 SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 532 SOUTH KOREA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 533 SOUTH KOREA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 534 SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 376 TABLE 535 SOUTH KOREA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 376 TABLE 536 SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 377 TABLE 537 SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 377 TABLE 538 SOUTH KOREA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 377 TABLE 539 SOUTH KOREA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 378 TABLE 540 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 378 TABLE 541 REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 542 REST OF ASIA PACIFIC: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 543 REST OF ASIA PACIFIC: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 544 REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 545 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 381 TABLE 546 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 381 TABLE 547 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 382 TABLE 548 REST OF ASIA PACIFIC: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 382 TABLE 549 REST OF ASIA PACIFIC: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 383 TABLE 550 LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 383 TABLE 551 LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 384 TABLE 552 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 384 TABLE 553 LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 384 TABLE 554 LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 555 LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 385 TABLE 556 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 386 TABLE 557 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 386 TABLE 558 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 386 TABLE 559 LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 387 TABLE 560 LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 387 TABLE 561 BRAZIL: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 388 TABLE 562 BRAZIL: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 563 BRAZIL: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 564 BRAZIL: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 389 TABLE 565 BRAZIL: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 390 TABLE 566 BRAZIL: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 390 TABLE 567 BRAZIL: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 391 TABLE 568 BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 391 TABLE 569 BRAZIL: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 391 TABLE 570 BRAZIL: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 392 TABLE 571 MEXICO: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 392 TABLE 572 MEXICO: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 573 MEXICO: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 574 MEXICO: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 575 MEXICO: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 576 MEXICO: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 395 TABLE 577 MEXICO: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 395 TABLE 578 MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 395 TABLE 579 MEXICO: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 396 TABLE 580 MEXICO: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 396 TABLE 581 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 397 TABLE 582 REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 397 TABLE 583 REST OF LATIN AMERICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 584 REST OF LATIN AMERICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 585 REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 586 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 399 TABLE 587 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 400 TABLE 588 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 400 TABLE 589 REST OF LATIN AMERICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 401 TABLE 590 REST OF LATIN AMERICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 401 TABLE 591 MIDDLE EAST: EPIGENETICS MARKET, BY REGION, 2024–2031 (USD MILLION) 402 TABLE 592 MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 402 TABLE 593 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 402 TABLE 594 MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 595 MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 403 TABLE 596 MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 597 MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 404 TABLE 598 MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 405 TABLE 599 MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 405 TABLE 600 MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 405 TABLE 601 MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 406 TABLE 602 GCC COUNTRIES: EPIGENETICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 406 TABLE 603 GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 407 TABLE 604 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407 TABLE 605 GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 407 TABLE 606 GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 408 TABLE 607 GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 408 TABLE 608 GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 409 TABLE 609 GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 409 TABLE 610 GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 409 TABLE 611 GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 410 TABLE 612 GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 410 TABLE 613 SAUDI ARABIA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 411 TABLE 614 SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 615 SAUDI ARABIA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 616 SAUDI ARABIA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 617 SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 413 TABLE 618 SAUDI ARABIA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 413 TABLE 619 SAUDI ARABIA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 414 TABLE 620 SAUDI ARABIA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 414 TABLE 621 SAUDI ARABIA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 414 TABLE 622 SAUDI ARABIA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 415 TABLE 623 UAE: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 415 TABLE 624 UAE: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 625 UAE: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416 TABLE 626 UAE: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 627 UAE: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 628 UAE: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 418 TABLE 629 UAE: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 418 TABLE 630 UAE: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 418 TABLE 631 UAE: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 419 TABLE 632 UAE: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 419 TABLE 633 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 420 TABLE 634 REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 420 TABLE 635 REST OF GCC COUNTRIES: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 421 TABLE 636 REST OF GCC COUNTRIES: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 421 TABLE 637 REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 422 TABLE 638 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 422 TABLE 639 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 423 TABLE 640 REST OF GCC COUNTRIES: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 423 TABLE 641 REST OF GCC COUNTRIES: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 424 TABLE 642 REST OF GCC COUNTRIES: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 424 TABLE 643 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 425 TABLE 644 REST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 645 REST OF MIDDLE EAST: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 426 TABLE 646 REST OF MIDDLE EAST: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 426 TABLE 647 REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 427 TABLE 648 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 427 TABLE 649 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 428 TABLE 650 REST OF MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 428 TABLE 651 EST OF MIDDLE EAST: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 429 TABLE 652 REST OF MIDDLE EAST: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 429 TABLE 653 AFRICA: EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 430 TABLE 654 AFRICA: EPIGENETICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 655 AFRICA: EPIGENETICS KITS & REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 656 AFRICA: EPIGENETICS ENZYMES MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 657 AFRICA: EPIGENETICS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 432 TABLE 658 AFRICA: EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 432 TABLE 659 AFRICA: EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION) 433 TABLE 660 AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 433 TABLE 661 AFRICA: EPIGENETICS PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 433 TABLE 662 AFRICA: EPIGENETICS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 434 TABLE 663 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, JANUARY 2023–MAY 2026 435 TABLE 664 EPIGENETICS MARKET: DEGREE OF COMPETITION 439 TABLE 665 EPIGENETICS MARKET: REGION FOOTPRINT 444 TABLE 666 EPIGENETICS MARKET: PRODUCT FOOTPRINT 445 TABLE 667 EPIGENETICS MARKET: SERVICE FOOTPRINT 446 TABLE 668 EPIGENETICS MARKET: METHOD FOOTPRINT 447 TABLE 669 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 450 TABLE 670 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 451 TABLE 671 EPIGENETICS MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–MAY 2026 454 TABLE 672 EPIGENETICS MARKET: DEALS, JANUARY 2023–MAY 2026 455 TABLE 673 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 456 TABLE 674 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 457 TABLE 675 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 460 TABLE 676 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–MAY 2026 460 TABLE 677 ILLUMINA, INC.: COMPANY OVERVIEW 462 TABLE 678 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 464 TABLE 679 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 466 TABLE 680 ILLUMINA, INC.: DEALS, JANUARY 2023–MAY 2026 467 TABLE 681 MERCK KGAA: COMPANY OVERVIEW 468 TABLE 682 MERCK KGAA: PRODUCTS/SERVICES OFFERED 469 TABLE 683 DANAHER CORPORATION: COMPANY OVERVIEW 472 TABLE 684 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 473 TABLE 685 DANAHER CORPORATION: DEALS, JANUARY 2023–MAY 2026 475 TABLE 686 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 476 TABLE 687 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 477 TABLE 688 REVVITY: COMPANY OVERVIEW 482 TABLE 689 REVVITY: PRODUCTS/SERVICES OFFERED 483 TABLE 690 PACBIO: COMPANY OVERVIEW 485 TABLE 691 PACBIO: PRODUCTS/SERVICES OFFERED 486 TABLE 692 PACBIO: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 487 TABLE 693 PACBIO: DEALS, JANUARY 2023–MAY 2026 488 TABLE 694 ACTIVE MOTIF, INC.: COMPANY OVERVIEW 489 TABLE 695 ACTIVE MOTIF, INC.: PRODUCTS/SERVICES OFFERED 489 TABLE 696 ACTIVE MOTIF, INC.: DEALS, JANUARY 2023–MAY 2026 492 TABLE 697 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 493 TABLE 698 NEW ENGLAND BIOLABS: PRODUCTS/SERVICES OFFERED 493 TABLE 699 NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 495 TABLE 700 NEW ENGLAND BIOLABS: DEALS, JANUARY 2023–MAY 2026 496 TABLE 701 QIAGEN: COMPANY OVERVIEW 497 TABLE 702 QIAGEN: PRODUCTS/SERVICES OFFERED 498 TABLE 703 QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 499 TABLE 704 ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW 500 TABLE 705 ZYMO RESEARCH CORPORATION: PRODUCTS/SERVICES OFFERED 500 TABLE 706 ZYMO RESEARCH CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 503 TABLE 707 ZYMO RESEARCH CORPORATION: DEALS, JANUARY 2023–MAY 2026 503 TABLE 708 HOLOGIC DIAGENODE: COMPANY OVERVIEW 504 TABLE 709 HOLOGIC DIAGENODE: PRODUCTS/SERVICES OFFERED 505 TABLE 710 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 508 TABLE 711 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 509 TABLE 712 PROMEGA CORPORATION: COMPANY OVERVIEW 511 TABLE 713 PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED 511 TABLE 714 EPIGENTEK GROUP INC.: COMPANY OVERVIEW 513 TABLE 715 EPIGENTEK GROUP INC.: PRODUCTS/SERVICES OFFERED 513 TABLE 716 EPIGENTEK GROUP INC.: PRODUCT LAUNCHES, JANUARY 2023–MAY 2026 517 TABLE 717 EPICYPHER: COMPANY OVERVIEW 519 TABLE 718 FIOS GENOMICS: COMPANY OVERVIEW 520 TABLE 719 GENOMESCAN: COMPANY OVERVIEW 521 TABLE 720 CREATIVE BIOGENE: COMPANY OVERVIEW 522 TABLE 721 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW 523 TABLE 722 ABNOVA CORPORATION: COMPANY OVERVIEW 524 TABLE 723 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 525 TABLE 724 BIOMODAL: COMPANY OVERVIEW 526 TABLE 725 10X GENOMICS: COMPANY OVERVIEW 527 TABLE 726 NOVOGENE CO., LTD.: COMPANY OVERVIEW 528 TABLE 727 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 541 TABLE 728 RISK ASSESSMENT 543 FIGURE 1 EPIGENETICS MARKET SEGMENTATION 47 FIGURE 2 EPIGENETICS MARKET: REGIONAL SCOPE 48 FIGURE 3 EPIGENETICS MARKET: YEARS CONSIDERED 49 FIGURE 4 MARKET SCENARIO 51 FIGURE 5 GLOBAL EPIGENETICS MARKET, 2024–2031 52 FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, 2023–2026 53 FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF EPIGENETICS MARKET 54 FIGURE 8 HIGH-GROWTH SEGMENTS IN EPIGENETICS MARKET, 2026–2031 55 FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN EPIGENETICS MARKET DURING FORECAST PERIOD 56 FIGURE 10 GROWING EMPHASIS ON POPULATION SCREENING PROGRAMS TO DRIVE MARKET 57 FIGURE 11 DNA METHYLATION ACCOUNTED FOR LARGEST SHARE OF EPIGENETICS MARKET IN NORTH AMERICA IN 2025 58 FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 59 FIGURE 13 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD 59 FIGURE 14 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 15 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 68 FIGURE 16 EPIGENETICS MARKET: VALUE CHAIN ANALYSIS 72 FIGURE 17 EPIGENETICS MARKET: ECOSYSTEM ANALYSIS 74 FIGURE 18 EPIGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84 FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2023–2026 86 FIGURE 20 PATENT APPLICATIONS IN EPIGENETICS MARKET, JANUARY 2015–DECEMBER 2025 96 FIGURE 21 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET 99 FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 113 FIGURE 23 KEY BUYING CRITERIA, BY END USER 114 FIGURE 24 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (MILLION UNITS) 126 FIGURE 25 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT 303 FIGURE 26 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT 352 FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN EPIGENETICS MARKET, 2021–2025 437 FIGURE 28 EPIGENETICS MARKET SHARE ANALYSIS, 2025 438 FIGURE 29 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 442 FIGURE 30 EPIGENETICS MARKET: COMPANY FOOTPRINT 443 FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 449 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 452 FIGURE 33 EV/EBITDA OF KEY VENDORS 452 FIGURE 34 EPIGENETICS MARKET: BRAND COMPARATIVE ANALYSIS 453 FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 457 FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 463 FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025) 469 FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 473 FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 477 FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025) 483 FIGURE 41 PACBIO: COMPANY SNAPSHOT (2025) 486 FIGURE 42 QIAGEN: COMPANY SNAPSHOT (2025) 498 FIGURE 43 HOLOGIC DIAGENODE: COMPANY SNAPSHOT (2025) 504 FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 509 FIGURE 45 EPIGENETICS MARKET: RESEARCH DESIGN 529 FIGURE 46 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES 532 FIGURE 47 EPIGENETICS MARKET: INSIGHTS FROM PRIMARIES 533 FIGURE 48 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025 534 FIGURE 49 EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2025 535 FIGURE 50 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025) 535 FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 537 FIGURE 52 EPIGENETICS MARKET: CAGR PROJECTIONS 539 FIGURE 53 EPIGENETICS MARKET: DATA TRIANGULATION 540

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們